Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sophiris Bio has reported a net loss of $5.62m, or $0.03 per share, for the third quarter ended 30 September 2012 compared to a net loss of $2.97m, or $0.02 per share, for the third quarter ended 30 September 2011.
Subscribe to our email newsletter
Expenses for third quarter of 2012 were $5.39m compared to $2.64m for the third quarter of 2011.
The company reported a net loss of $15.84m, or $0.10 per share, for the nine months ended 30 September 2012 compared to a net loss of $8.52m, or $0.07 per share, for the nine months ended 30 September 2011.
Expenses of $14.53m were reported for the first nine months of 2012 compared to $8.13m for the first nine months of 2011.
The company attributes increase in research and development expenses to the PRX302 clinical program, specifically the on-going transrectal study and clinical material manufacturing expenses.